Halozyme Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Halozyme Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Halozyme Therapeutics Inc Strategy Report
- Understand Halozyme Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded recombinant formulation of rHuPH20, which facilitates the administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and enhanced resorption of radiopaque agents in subcutaneous urography. The company also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20. It works in partnership with Pfizer, Roche and Janssen, among others, for advancing the treatment of various types of cancers. Halozyme is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
12390 El Camino Real, San Diego, California, 92130
Website
www.halozyme.com
Telephone
1 858 7948889
No of Employees
373
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HALO (NASD)
Revenue (2022)
$829.3M
25.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
39.3%
(2022 vs 2021)
Market Cap*
$4.8B
Net Profit Margin (2023)
XYZ
10.9%
(2022 vs 2021)
* As of and is in US$
Halozyme Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Hylenex Recombinant | Hylenex |
| Enhanze Drug Delivery Technology | Enhanze |
| XYOSTED Testosterone enanthate injection | XYOSTED |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In January, the company secured approval from the U.S. Food and Drug Administration for HYQVIA [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE drug delivery technology to treat patients with chronic inflammatory demyelinating polyneuropathy (CIDP). |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Acumen Pharmaceuticals under which Acumen will explore the potential use of ENHANZE for ACU193. |
| 2022 | Acquisitions/Mergers/Takeovers | In May, the company acquired Antares Pharma Inc. |
Competitor Comparison
| Key Parameters | Halozyme Therapeutics Inc | Celltrion Inc | Amphastar Pharmaceuticals Inc | CTI BioPharma Corp | Avanir Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | South Korea | United States of America | United States of America | United States of America |
| City | San Diego | Incheon | Rancho Cucamonga | Seattle | Aliso Viejo |
| State/Province | California | - | California | Washington | California |
| No. of Employees | 373 | 1,074 | 1,761 | 128 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeffrey W. Henderson | Chairman | Executive Board | 2015 | 58 |
| Helen I. Torley | Chief Executive Officer; Director; President | Executive Board | 2014 | 60 |
| Nicole LaBrosse | Chief Financial Officer | Senior Management | 2022 | 40 |
| Cortney Caudill | Chief Operating Officer | Senior Management | 2023 | - |
| Mark Snyder | Chief Compliance Officer; General Counsel; Corporate Secretary; Senior Vice President | Senior Management | 2022 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward